Petros Grivas – Candidate for ASCO Nominating Committee

Petros Grivas has been nominated as the Undesignated Member Candidate of the nomination committee for ASCO.

The ASCO Nominating Committee has selected 13 distinguished members as candidates for leadership positions within the Society.

ASCO encourages all eligible members to vote for the new leaders of the Society.
Eligible members include those holding a Doctor of Medicine, Doctor of Osteopathy, Doctor of Philosophy, Doctor of Pharmacy, Doctor of Medical Science, Doctor of Nursing Science, Doctor of Nursing Practice, or an equivalent doctoral-level degree recognized by the Society and the Association, and who are in good standing as of October 14, 2024. Voting in the ASCO Election will earn eligible members a FASCO point.

The voting period ends on Tuesday, December 3, 2024, at 3:00 PM Eastern Standard Time. All ballots, whether submitted online or by paper, must be received by this deadline.

Petros Grivas is nominated alongside Rana McKay, Erika P. Hamilton, and Flavio G. Rocha.

Petros Grivas, MD, PHD, is a Professor in the Department of Medicine, Division of Hematology-Oncology at the University of Washington and in the Clinical Research Division at Fred Hutchinson Cancer Center.

Dr. Petros Grivas has held several academic and clinical positions throughout his career. From 2013 to 2014, he served as a Clinical Lecturer in the Division of Hematology/Oncology at the University of Michigan.

He then moved to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, where he was appointed Clinical Assistant Professor of Medicine from 2016 to 2017. In 2018, Dr. Grivas joined the University of Washington as an Associate Professor in the Department of Medicine, Division of Medical Oncology, and also became an Associate Professor in the Clinical Research Division at Fred Hutchinson Cancer Center.

He has served at the University of Washington, where he served as Clinical Director of the Genitourinary Cancers Program since 2018 and as Interim Research Director for the Phase I Program in 2019.

From 2013 to 2014, Dr. Petros Grivas served as a Clinical Lecturer in the Division of Hematology/Oncology at the University of Michigan.

He then joined the Taussig Cancer Institute at the Cleveland Clinic Foundation, first as an Associate Staff member from 2014 to 2016, and later as a Staff member in the Department of Hematology & Medical Oncology from 2017.

Since 2018, Dr. Grivas has been affiliated with the University of Washington Medical Center and Fred Hutch Cancer Center, where he currently serves as the Clinical Director of the Genitourinary Cancers Program.

His other affiliations include the American College of Physicians (ACP) from 2008 to 2010, the American Medical Association (AMA) from 2011 to 2012, and the American Association for Cancer Research (AACR) from 2011 to 2022. He has been a member of the American Society of Clinical Oncology (ASCO) and SWOG since 2011, and of ECOG-ACRIN since 2014.

Dr. Grivas is also involved with the Bladder Cancer Advocacy Network (BCAN), the International Bladder Cancer Network (IBCN), and the European Society of Medical Oncology (ESMO), all of which he has been a part of since 2014 and 2016, respectively. Additionally, he is a member of the International Bladder Cancer Group (IBCG).

Dr. Petros Grivas has served on the editorial boards of numerous medical and oncology journals throughout his career.

His editorial responsibilities began in 2009 with the Journal of Medical Genetics and Genomics (JMGG), the Journal of Clinical Pathology and Forensic Medicine (JCPFM), and the Journal of Cancer Research and Experimental Oncology (JCREO).

He also serves as an editor for the Bladder Cancer Center of Excellence for UroToday and Practice Update, and in 2021, he became part of the specialty section in Genitourinary Oncology within Frontiers in Oncology.

Dr. Petros Grivas has also taken on numerous special local responsibilities at Fred Hutchinson Cancer Center (FHCC) and the University of Washington (UW). Since 2018, he has been a member of the FHCC “Physician Burnout” Committee.

As a founding member of the “Dimitrios Grivas” cancer research fund at UW in 2021, he has worked to advance research and patient care.

Education

Petros Grivas earned his MD and Ph.D. in Medical Oncology from the University of Patras School of Medicine in Greece, completing his medical degree in 2005 and his doctoral studies in 2009.

His postgraduate training includes a year-long program in Clinical and Laboratory Studies at the University of Patras, where he gained expertise in molecular biology, biostatistics, and bioinformatics.

He then completed an Internal Medicine residency at Drexel University College of Medicine and Hahnemann University Hospital in Philadelphia from 2007 to 2010.

Dr. Grivas pursued further specialization through a Fellowship in Hematology/Oncology at the University of Michigan, followed by leadership development programs such as the GME Scholars Health Care Administration and Leadership Program at Michigan, the ASCO Leadership Development Program, and the Harvard Business School Strategy for Health Care Delivery Program. More recently, in 2022, he participated in the WSMA Dyad Leadership Course at the Fred Hutchinson Cancer Center.

Awards and Honors

• 2016: Cleveland Clinic Caregiver Celebrations Awards
• 2016: CARES (Scott Hamilton & Friends) Award for research
• 2017: GU Malignancies Pilot Award, Case Comprehensive Cancer Center
• 2018: Selected by University of Washington to apply for Andy Hill CARE Award
• 2019: Albert Institute Bladder Cancer Care & Research (2 funded/awarded projects)
• 2020: Co-investigator on awarded/funded grant (Cascadia; PI: Dr. Fredricks)
• 2020 & 2021: Kure It Cancer Research Award/Grant to UW
• 2022: Healio Next Generation “Disruptor” Award for innovative research (ceremony during ASCO Annual Meeting)
• 2023: Uromigos Meeting Cup winner (with Drs. Tanya Dorff and Sumanta Pal)
• 2024: ASCO Ambassador
• 2024: Ambassador for ESMO’24 Congress
• 2024: Uromigos Meeting Cup winner (with Drs. Tanya Dorff and Dave McDermott)

Interviews with Petros Gravis

Petros Grivas on the Efficacy of Sacituzumab Govitecan for Bladder Cancer. – GU Oncology Now. (November 2022).

Prof. Petros Grivas” reflections from the World Bladder Cancer Patient Forum 2023. – World Bladder Cancer Patient Coalition (August 2024).

Meet Petros Grivas, M.D., Ph.D., Medical Oncology Care Provider | UW Medicine (August 2018)

For more posts like this, visit oncodaily.com